Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma

摘要

Treatment overview. a The schedule of two rounds of intracranial infusion of B7-H3 targeted CAR-T cells. The intracranial infusion was interrupted for 1 week after each round for assessment of safety and disease. Since the patient requested to be discharged 5 days after cycle 6 infusion and dropped out of the clinical study after cycle 7 infusion, further analysis of CAR-T therapy and resistance of post-therapy were limited. b Coronal, sagittal, and axial MRI of the brain before and after the first 3-cycles CAR-T cells infusion (day 21 and 49). Red dotted box highlighted the site of the resected tumor region. c Total nucleated cell and T cell count in the CSF, obtained from the delivery device before and after the infusion cycle 1, 3, 4, and 6. The results showed the mean values of triplicate technical repeats. Flow cytometry analysis of the T cell ratio in total nucleated cell indicated that expansion of T cells after delivery of CAR-T cell. d The significant cytokines changes in CSF and serum before and after each cycle infusion